僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein （rFVIIIFc） with an extended half-life compared with conventional factor VIII （FVIII） preparations, including recombinant FVIII （rFVIII） products such as Moroctocog alfa1. It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A （congenital factor VIII deficiency）.